UT Austin licenses unique delivery technique for AMD

Patient compliance has long been a problem associated with treatment of wet type age-related macular degeneration (AMD). Current treatment is simply not very pleasant and may require many painful injections over six months. A longtime goal among pharmaceutical companies is to develop something easier for drug delivery to the back of the eye. The University of Texas at Austin is licensing what it says is a unique solution for wet type AMD drug delivery. The treatment involves a one-time implantation of a carrier system for the drug. Then, each time the patient needs medication, the doctor can operate a laser beam to release it in measurable doses. More

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.